Takeda Pharmaceutical
About: Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Employees: 49,281
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
4,520% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $496K
7% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 94
7% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 42
0.26% less ownership
Funds ownership: 4.79% [Q3] → 4.53% (-0.26%) [Q4]
1% less funds holding
Funds holding: 298 [Q3] → 294 (-4) [Q4]
6% less capital invested
Capital invested by funds: $1.02B [Q3] → $954M (-$62.3M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TAK.
Financial journalist opinion
Based on 6 articles about TAK published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Neutral
Accesswire
1 week ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP).
Positive
Zacks Investment Research
2 weeks ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Seeking Alpha
2 weeks ago
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, supports a "Strong Buy" rating for high-risk tolerant investors.
Positive
Zacks Investment Research
2 weeks ago
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Positive
Zacks Investment Research
4 weeks ago
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Zacks Investment Research
1 month ago
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Neutral
Seeking Alpha
1 month ago
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet future clinical demand. The firm has been a proven cash flow generator, with an above-average dividend yield above +4%, and modest leverage risk.
Positive
Zacks Investment Research
1 month ago
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Business Wire
1 month ago
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first.
Charts implemented using Lightweight Charts™